公开(公告)号：US12029780B2

公开(公告)日：2024-07-09

申请号：US17549017

申请日：2021-12-13

申请人： OPKO BIOLOGICS LTD.

发明人： Fuad Fares ,  Udi Eyal Fima

IPC分类号： A61K38/27 ,  A61K38/24 ,  A61K47/00 ,  A61K47/02 ,  A61K47/12 ,  C07K14/475 ,  C07K14/505 ,  C07K14/555 ,  C07K14/59 ,  C07K14/61 ,  C07K19/00 ,  G01N33/74

CPC分类号： A61K38/27 ,  A61K38/24 ,  A61K47/02 ,  A61K47/12 ,  C07K14/505 ,  C07K14/555 ,  C07K14/59 ,  C07K14/61 ,  G01N33/74 ,  C07K2319/00 ,  C07K2319/31 ,  G01N2333/65 ,  G01N2800/52

摘要： CTP-modified human growth hormone polypeptides and pharmaceutical formulations and pharmaceutical compositions comprising the same and methods of producing, and using the same are disclosed.

公开(公告)号：US20230321220A1

公开(公告)日：2023-10-12

申请号：US18043354

申请日：2021-08-27

申请人： JOINT STOCK COMPANY "BIOCAD"

发明人： Alexander Vladimirovich PROKOFYEV ,  Pavel Mikhailovich GERSHOVICH ,  Anna Nikolaevna STRELKOVA ,  Natalia Aleksandrovna SPIRINA ,  Diana Aleksandrovna KONDINSKAIA ,  Pavel Andreevich IAKOVLEV ,  Dmitry Valentinovich MOROZOV

IPC分类号： A61K39/215 ,  C12N15/86 ,  C07K14/005 ,  C07K14/61 ,  A61P31/12

CPC分类号： A61K39/215 ,  C12N15/86 ,  C07K14/005 ,  C07K14/61 ,  A61P31/12 ,  C12N2770/20022 ,  C12N2770/20034 ,  C12N2770/20071 ,  C12N2750/14143 ,  A61K2039/5256

摘要： The present application relates to the fields of biotechnology, immunology, virology, genetics, and molecular biology. More specifically, the present invention relates to an isolated recombinant receptor-binding domain of the S glycoprotein (RBD-S) of SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2), to a nucleic acid that encodes RBD-S of SARS-CoV-2, to an expression cassette and a vector based thereon, as well as to a recombinant AAV5 (adeno-associated vims serotype 5)-based virus for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection, to an AAV5-based vaccine for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection, and to their use for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection.

公开(公告)号：US20230242574A1

公开(公告)日：2023-08-03

申请号：US17990492

申请日：2022-11-18

申请人： UBIPROTEIN, CORP.

发明人： Kyunggon Kim ,  Kwang-Hyun Baek ,  Sung-Ryul Bae ,  Myung-Sun Kim ,  Hyeonmi Kim ,  Yeeun Yoo ,  Lan Li ,  Jung-Hyun Park ,  Jin-Ok Kim

IPC分类号： C07K1/107 ,  C07K14/49 ,  C07K14/50 ,  C07K14/505 ,  C07K14/51 ,  C07K14/535 ,  C07K14/56 ,  C07K14/565 ,  C07K14/575 ,  C07K14/605 ,  C07K14/61 ,  C07K14/62 ,  C07K16/00

CPC分类号： C07K1/1075 ,  C07K14/49 ,  C07K14/50 ,  C07K14/505 ,  C07K14/51 ,  C07K14/535 ,  C07K14/56 ,  C07K14/565 ,  C07K14/575 ,  C07K14/5759 ,  C07K14/605 ,  C07K14/61 ,  C07K14/62 ,  C07K16/00 ,  A61K38/00

摘要： The present invention relates to a method for prolonging half-life of a protein or a (poly)peptide by replacing one or more amino acid residues of the protein. Further, the present invention is about the protein having a prolonged half-life prepared by the method above.

公开(公告)号：US11634474B2

公开(公告)日：2023-04-25

申请号：US17323733

申请日：2021-05-18

申请人： JCR Pharmaceuticals Co., Ltd.

发明人： Kenichi Takahashi ,  Aya Yoshioka ,  Hideto Morimoto ,  Masafumi Kinoshita

IPC分类号： C07K14/765 ,  A61K38/00 ,  C12N5/16 ,  C07K19/00 ,  C12N15/09 ,  A61P43/00 ,  A61P3/00 ,  A61P5/06 ,  C07K14/61

摘要： Disclosed are a human serum albumin mutant that can be linked to a physiologically active protein to increase the stability of the protein in the blood, as well as a resulting protein produced by linking with the mutant. The protein produced by linking with the mutant consists of a human serum albumin mutant comprising the amino acid sequence set forth as SEQ ID NO:3 or an amino acid sequence that, in comparison with it, lacks not more than 10 amino acid residues and/or has not more than 10 amino acid residues replaced, with the proviso that the asparagine residue occurring at position 318 and the threonine at position 320 from the N-terminus of the amino acid sequence set forth as SEQ ID NO:3 are preserved and linked by peptide bonds via a single amino acid residue (X) except proline placed between those two amino acid residues, and a physiologically active protein linked to the mutant.

公开(公告)号：US11613737B2

公开(公告)日：2023-03-28

申请号：US16841539

申请日：2020-04-06

申请人： Prevail Therapeutics, Inc.

发明人： Asa Abeliovich ,  Laura Heckman ,  Herve Rhinn

IPC分类号： C12N7/00 ,  C07K14/47 ,  A61K35/76 ,  C07K14/005 ,  C07K14/61 ,  C07K14/705 ,  C07K14/435 ,  A61K35/761 ,  C12N15/861 ,  C12N15/86 ,  C12N15/864 ,  A61P25/28 ,  A61K9/00 ,  A61K48/00 ,  A61P25/16 ,  A61K39/23 ,  C07H21/04

摘要： The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease (PD) and Gaucher disease. In some embodiments, the disclosure provides expression constructs comprising a transgene encoding beta-Glucocerebrosidase (GBA) or a portion thereof alone or in combination with one or more PD-associated genes. In some embodiments, the disclosure provides methods of Parkinson's disease by administering such expression constructs to a subject in need thereof.

公开(公告)号：US20220290165A1

公开(公告)日：2022-09-15

申请号：US17529931

申请日：2021-11-18

申请人： GLYKOS FINLAND OY

发明人： Christopher LANDOWSKI ,  Anne HUUSKONEN ,  Juhani SAARINEN ,  Ann WESTERHOLM-PARVINEN ,  Anne KANERVA ,  Jari NATUNEN ,  Anna-Liisa HÄNNINEN ,  Noora SALOVUORI ,  Merja PENTTILÄ ,  Markku SALOHEIMO

IPC分类号： C12N15/80 ,  C12P21/00 ,  C12P21/02 ,  C12N9/58 ,  C07K16/00 ,  C07K16/28 ,  C07K14/56 ,  C07K14/61 ,  C07K14/65

摘要： The present disclosure relates to compositions and methods useful for the production of heterologous proteins in filamentous fungal cells.

公开(公告)号：US20220054602A1

公开(公告)日：2022-02-24

申请号：US17465287

申请日：2021-09-02

申请人： Translate Bio, Inc.

发明人： Braydon Charles Guild ,  Michael Heartlein ,  Frank DeRosa

IPC分类号： A61K38/47 ,  A61K48/00 ,  C07K14/505 ,  C07K14/61 ,  C12N15/67 ,  C12N9/10 ,  C12N9/40 ,  A61K38/27 ,  A61K38/45 ,  A61K38/18

摘要： Compositions for modulating the expression of a protein in a target cell comprising at least one RNA molecule which comprises at least one modification 5 conferring stability to the RNA, as well as related methods, are disclosed.

公开(公告)号：US11197915B2

公开(公告)日：2021-12-14

申请号：US15200813

申请日：2016-07-01

申请人： OPKO Biologies Ltd.

发明人： Fuad Fares ,  Udi Eyal Fima

IPC分类号： A61K38/27 ,  C07K14/61 ,  C07K14/59 ,  A61K38/24 ,  C07K14/555 ,  C07K14/505 ,  A61K47/02 ,  A61K47/12 ,  G01N33/74

摘要： CTP-modified human growth hormone polypeptides and pharmaceutical formulations and pharmaceutical compositions comprising the same and methods of producing, and using the same are disclosed.

公开(公告)号：US11168125B2

公开(公告)日：2021-11-09

申请号：US16518642

申请日：2019-07-22

申请人： BIOVERATIV THERAPEUTICS INC.

发明人： Robert T. Peters ,  Adam R. Mezo ,  Daniel S. Rivera ,  Alan J. Bitonti ,  Susan C. Low

IPC分类号： C07K14/755 ,  C07K14/475 ,  C07K14/505 ,  C07K14/555 ,  C07K14/56 ,  C07K14/745 ,  C07K16/00 ,  C12N9/64 ,  A61K47/68 ,  C07K14/565 ,  C12N9/96 ,  A61K47/60 ,  C07K14/59 ,  C07K14/61 ,  C07K14/705 ,  A61K47/64 ,  A61K38/00

摘要： The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.

公开(公告)号：US20210283264A1

公开(公告)日：2021-09-16

申请号：US17142698

申请日：2021-01-06

申请人： Ascendis Pharma GmbH

发明人： Ulrich Hersel ,  Harald Rau ,  Robert Schnepf ,  Dirk Vetter ,  Thomas Wegge

IPC分类号： A61K47/58 ,  A61K47/64 ,  A61K47/60 ,  A61K47/69 ,  A61K47/61 ,  C07C69/96 ,  C07D207/46 ,  C07D401/12 ,  C07K14/00 ,  C07K14/61 ,  C07K14/62

摘要： A cascade carrier linked prodrug is described comprising a biologically active moiety and a masking group having at least one nucleophile and being distinct from the carrier.